NEW STUDY. A new blood test called p-tau217 shows promise as an Alzheimer’s disease biomarker, and when used in a two-step workflow very high accuracy to either identify or exclude brain amyloidosis, the most important and earliest pathology. That is an innovation now presented by researchers at the University of Gothenburg, together with colleagues at University of Lund and in Montreal, Canada. In recent years, a lot of effort has…
Good fitness levels in youth linked to lower cancer risk
NEW STUDY. Men who have higher aerobic fitness at age 18 have a lower risk of several forms of cancer later in life, especially cancers of the gastrointestinal tract. This has been shown by a study at the University of Gothenburg. It is already known that physical activity can prevent certain types of cancer. The new study has examined the link between aerobic fitness at the time of military conscription…
A new treatment for osteoarthritis in horses and potentially humans
NEW STUDY. For the first time, an intervention has emerged that seems competent in slowing down osteoarthritis (OA) progression. In a clinical study from SLU and University of Gothenburg, wherein the OA horses treated with this drug became completely free from lameness with a simultaneous impediment of the joint tissue degradation. It could be worth exploring this drug for human OA intervention as well. OA is an inflammatory-whole joint disease…
Engineered approach to remove protein aggregates from cells
NEW STUDY. Protein aggregates accumulate during aging and are linked to neurodegenerative diseases like Alzheimer’s, Parkinson’s or Huntington’s disease. A new study by the Nyström lab at University of Gothenburg, in collaboration with the Max Planck Institute for Biology of Ageing in Germany, describes a novel, engineered approach that makes protein aggregates amenable to spatial manipulations in both budding yeast and human cells. Many neurodegenerative diseases like Alzheimer’s, Parkinson’s or…
International research collaboration expands understanding of rare heart defect
NEW STUDY. By collaborating with researchers at Rigshospitalet and the University of Copenhagen, researchers at Sahlgrenska University Hospital and Sahlgrenska Academy have been able to create the largest cohort of patients to date with the rare heart defect Ebstein anomaly. The collaboration enables completely new opportunities for studying comorbidity and survival over time. In Sweden more than four babies are born annually with the heart defect Ebstein anomaly. Those with…